Abstract | INTRODUCTION: METHODS: We recruited 108 patients (92 men, mean age 64 +/- 12 years) with STEMI, of whom 84 (78%) received thrombolytic treatment with rtPA and 24 (22%) did not. MMP-2 and MMP-9 levels were assessed at hospital admission (baseline), and at 24 and 72 h after admission, using a commercially available ELISA. RESULTS: Overall, MMP-9 levels were higher in the thrombolysis group compared to patients without thrombolysis (p < 0.001). Thrombolysis treatment significantly affected the change in MMP-9 levels during the 72-h study period (p < 0.001). CONCLUSIONS: The present study showed that thrombolysis could affect circulating levels of MMP-9 in STEMI patients. Whether this effect may lead to plaque instability deserves further investigation.
|
Authors | Dimitrios N Tziakas, Georgios K Chalikias, Eleni I Hatzinikolaou, Dimitrios A Stakos, Ioannis K Tentes, Alexandros Kortsaris, Dimitrios I Hatseras, Juan Carlos Kaski |
Journal | Thrombosis research
(Thromb Res)
Vol. 118
Issue 2
Pg. 221-7
( 2006)
ISSN: 0049-3848 [Print] United States |
PMID | 16126256
(Publication Type: Comparative Study, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Fibrinolytic Agents
- Tissue Plasminogen Activator
- Matrix Metalloproteinases
- Matrix Metalloproteinase 2
- Matrix Metalloproteinase 9
|
Topics |
- Aged
- Female
- Fibrinolytic Agents
(therapeutic use)
- Humans
- Male
- Matrix Metalloproteinase 2
(blood)
- Matrix Metalloproteinase 9
(blood)
- Matrix Metalloproteinases
(blood)
- Middle Aged
- Myocardial Infarction
(blood, diagnosis, drug therapy)
- Time Factors
- Tissue Plasminogen Activator
(therapeutic use)
|